Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | GFER | P55789 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | GLA | P06280 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587705 | 0.84 | ALDH1A1 (0.50) | RPS6KA3ALDH1A1MAPTNPC1MEN1 | |
| SCHEMBL417139 | 0.83 | NISCH (0.45) | ALDH1A1MAPTNPC1MEN1KMT2A | |
| SCHEMBL419320 | 0.80 | RAB9A (0.44) | ALDH1A1MAPTNPC1KDM4ERAB9A | |
| SCHEMBL416642 | 0.79 | POLB (0.56) | MAPTNPC1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL415765 | 0.79 | MAPK1 (0.47) | ALDH1A1MAPTNPC1MEN1KMT2A | |
| SCHEMBL823787 | 0.79 | MAPK13 (0.43) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2304276 | 0.79 | POLB (0.39) | MAPTNPC1RAB9APOLBGAA | |
| SCHEMBL416435 | 0.78 | POLB (0.60) | ALDH1A1MAPTNPC1KDM4ERAB9A | |
| SCHEMBL420012 | 0.77 | MGAM (0.43) | ALDH1A1MAPTNPC1KDM4ERAB9A | |
| SCHEMBL414390 | 0.76 | HDAC6 (0.47) | ALDH1A1NPC1KMT2AKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MACROGEN INC. (KR) | 2021-05-06 | — | — | US | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190050525-A1 | RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES | PSOMAGEN, INC. | 2019-02-14 | — | — | US | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| US-20160272617-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | US | disclosed |
| WO-2016131381-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2003035615-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272617-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | RPS6KA3 3145/4885ALDH1A1 1093/4885MAPT 2938/4885 |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MAOA, PNMT, HNMT | RPS6KA3 4501/4885ALDH1A1 959/4885MAPT 185/4885 |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | RPS6KA3 497/4885ALDH1A1 1376/4885MAPT 3263/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | RPS6KA3 3816/4885ALDH1A1 3573/4885MAPT 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.